Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (“Ollin”).
“We are pleased to expand our relationship with Johnson & Johnson by supporting the Phase 3 development of OLN324,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients’ lives.”
“OLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients,” said Kiran Reddy, Senior Managing Director at Blackstone Life Sciences. “We are excited to work with Johnson & Johnson to help advance this promising new treatment option to patients.”
The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.
David Vitek
(212) 583-5291
David.Vitek@Blackstone.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261115269157/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?
